The transcription factor C/EBP is known to be able to bind to two different classes of sites, a CAAT-box and one present in a number of viral enhancers. In this paper we show using band-shift assays, methylation interference and footprintlng that C/EBP is also able to bind with high affinity to ATF/CRE sites. Competition with mutant ATF sites and methylation interference indicate that C/EBP may be able to bind to the ATF/CRE sites by virtue of their homotogy to the enhancer core elements. Furthermore, we show that C/EBP Is able to direct transcription from this site In transient transfection experiments and that mutations in the ATF binding site that impair DNA binding also effect the ability of C/EBP to stimulate transcription.
INTRODUCTION
An essential step in the mechanism through which many transcription factors act is their binding to specific sites in the vicinity of target genes [1] . Some of these sites are bound by closely related proteins that constitute a family of transcription factors, for example fos/jun or ATF/CREB [2, 3] . In many cases, the individual members of the family of proteins have structural features in common but nevertheless have different regulatory functions. Conversely, some transcription factors are capable of binding to more than one site. Examples include the thyroid hormone receptor which binds to estrogen response elements as well as to its own response element [4] and the yeast pheromone/receptor transcription factor (PRTF) which binds to two mating-type specific elements [5] . Another well-characterised example is CAAT-box/enhancer binding protein (C/EBP). The protein was originally shown to bind to sequences present in different viral enhancers [6, 7, 8] and later it was found to bind to the CCAAT box, a sequence motif that has been identified in a large number of cellular promoters [9, 10, 11] . C/EBP expression itself appears to be restricted to a limited number of tissues [ 12] , in particular to liver and adipose tissue, and evidence is accumulating that it is a member of a larger family of transcription factors [13, 14, 15] .
During the course of our work on the androgen-regulated C3 gene, which is expressed in the rat prostate, we identified a CCAAT-box in it's proximal promoter region [16] . Surprisingly, we observed that adenovirus activation transcription factor (ATF) binding sites [17, 18] were able to compete for binding to this site, suggesting that the same factor could bind to these two sequence motifs. Here we show using band-shift and footprinting assays that the C/EBP protein that binds to the C3 CCAAT box is also able to bind to ATF sites and cyclic AMP response elements (CRE) with high affinity and that binding can result in a stimulation of transcription in transient transfection assays.
MATERIALS AND METHODS Piasmids
Plasmid pBS-CEBP was made by cloning a BamHI-Hindlll fragment from pMSV-CEBP-wt [9] containing the C/EBP open reading frame, into BamHI-Hindin digested pBlueScript SK (Stratagene Ltd, Cambridge, UK). Piasmids used in the transient transfection experiments were a chloramphenicol-acetyltransferase (CAT) based reporter containing two E4-ATF binding sites-without or with mutations-in front of the E4-TATA box, the C/EBP expression vector pMSV-CEBP-wt [9] and pJ3Luciferase.
Band-shift assays Band-shift assays were carried out using nuclear extracts from rat liver, in vitro synthesised C/EBP or an 88 amino acid Cterminal fragment of C/EBP. Rat liver nuclear extract was prepared using the method of Gorski et al. [19] as modified by Wall et al. [20] . Livers were removed from male Sprague Dawley rats, washed with ice-cold phosphate buffered saline and were then immediately used to prepare nuclear extracts. Proteinase inhibitors (phenylmethylsulfonyl fluoride, 0.1 mM; aprotinin, 10 /tg/ml; leupeptin, 10 /tg/ml; pepstatin, 10 /ig/ml; bacatracin, 0.1 %) were added after homogenization. After dissolving the final ammonium sulphate pellet in 0.5-1.0 ml of dialysis buffer [19] , the protein extract was dialysed overnight in a BRL microdialyser (Gibco Ltd, Paisley, UK) against two changes of 250 ml dialysis buffer at 4°C. The final concentration of the nuclear extracts was between 7 and 12 mg/ml as measured using the Bradford assay with bovine serum albumin as a standard [21] . Full length C/EBP was prepared by in vitro synthesising capped RNA from pBS-* To whom correspondence should be addressed CEBP using T3 RNA polymerase (Promega, Southampton, UK) which was then used to program rabbit reticulocyte lysate (Promega, Southampton, UK) using methods supplied by the manufacturer. In some experiments an 88 amino acid C-terminal fragment of C/EBP (rC/EBP) was used that was expressed in E. coli and purified as described [22] . Probes for the band-shift assays were obtained by labeling synthetic oligonucleotides with T4 polynucleotide kinase (Pharmacia Ltd, Milton Keynes, UK) using standard methods [23] . Liver nuclear extract (3 /tg), in vitro synthesised C/EBP or rC/EBP (0.5 ng) were incubated with probe (2 ng) for 30 min at room temperature in a buffer containing 25 mM Hepes (pH 7.5), 50 mM NaCl, lmM DTT, 10% glycerol and 1 mM EDTA with or without competitor oligonucleotides at different concentrations (see figure legends). Samples were then loaded on a 6% polyacrylamide gel in 0.5XTBE (50 mM Tris-borate pH 8.3, 0.5 mM EDTA) that was run at 10 V/cm. The gel was fixed in 30% methanol/10% glacial acetic acid, dried and exposed to X-ray film for 1 to 2 hours.
The dissociation constants (Kj) of in vitro synthesized C/EBP and rC/EBP were determined by incubating a fixed amount of protein with increasing concentrations of probe (0.02-50 ng). After separation of the bound and unbound DNA as described above, the gel was dried and the the amount of bound and free probe at the different concentrations quantified directly using a Ambis Systems /3-scanner. From these data a Scatchard plot was derived that yielded the Kj.
Methylation interference and footprinting
A 59 bp oligonucleotide spanning sequences -18 to -76 of the adenovirus E4 promoter was labelled at the appropriate end with T4 polynucleotide kinase. For methylation interference the probe was partially methylated as described [24] . This methylated oligonucleotide (20 ng) was added to 5 ng of rC/EBP and the resulting complex was separated from the unbound DNA on a non-denaturing 6% polyacrylamide gel. Bound and unbound DNA were eluted from the gel using an LKB Extraphor electrophoretic concentrator (Pharmacia Ltd, Milton Keynes, UK), precipitated, treated with pipyridine and run on a 10% denaturing poly-acrylamide gel.
Copper-phenanthroline footprinting of rC/EBP (5 ng) on the 59 bp E4 oligonucleotide (20 ng) labelled on either one of its ends was performed in the gel matrix as described [25] . Bound and unbound DNA were electroeluted as described above and samples were run on a 10% denaturing poly-acrylamide gel.
Transfection HeLa E cells were grown in Dulbecco's Modified Eagles Medium (DMEM) supplemented with 10% fetal calf serum (FCS). Cells were plated at 10 6 cells/9cm dish and were transfected with a chloramphenicol-acetyltransferase (CAT) based reporter containing two E4-ATF binding sites-without or with mutations-in front of the E4-TATA box (10 /tg), the C/EBP expression vector pMSV-CEBP-wt (5 ng) and, to check transfection efficiency, pJ3Luciferase (2 /tg) using the calcium phosphate method. Cells were harvested after 48 hr, and assayed for luciferase and CAT activity as previously described [26, 27] .
RESULTS
Preliminary experiments had shown that proteins binding to the CCAAT box of the rat C3 gene could be competed from this element by adenovirus ATF binding sites [16] . This competition with sites derived from the adenovirus E4 and E3 promoters, was also seen when a rat liver nuclear extract was incubated with an labelled oligonucleotide containing a palindromic C/EBP binding site (Fig. 1A) . That this complex was the result of C/EBP binding activity is indicated by the fact that its mobility was significantly increased ('supershifted') with a C/EBP-specific antiserum (Fig. IB) . This antiserum was also able to supershift both rC/EBP and in vitro synthesized C/EBP (Fig. IB and data  not shown) . Similarly, when a labelled E4-ATF binding site was incubated with rat liver nuclear extract, a number of complexes were observed one of which is 'supershifted' by the C/EBP specific antiserum, indicating that C/EBP is able to bind to this ATF site (Fig. IB) . However, neither purified ATF protein from HeLa cells nor in vitro synthesised CREB protein could bind to the C/EBP site (data not shown). To investigate whether competition was limited to the adenovirus ATF sites, we compared the ability of different ATF/CRE elements to compete for C/EBP binding. The ATF/CRE's of somatostatin, fibronectin and human a-choriogonadotrophin gene were also able to compete albeit at at least 5-fold higher concentrations when compared to the adenovirus sites (Fig. 2) . Weak or no competition was observed with NF-Y, cp-1, and AP-1 binding sites (Fig. 2) . Since the AP-1 site, which differs from the ATF/CRE site by the absence of the central C residue [1] , is not able to compete it suggests that the spacing of the bases is important for C/EBP binding. It is noteworthy that the ATF/CRE sites that competed less well for C/EBP binding all have a C residue in position 7 instead of an A. To test whether this single base change is responsible for the reduced ability of these binding sites to compete, an oligonucleotide based on somatostatin was synthesized in which the C was changed into an A. As shown in Figure 2 this mutant oligonucleotide was able to compete C/EBP binding at lower concentrations, confirming the importance of the A residue at position 7.
To study the binding characteristics in more detail we used a bacterially expressed 88 amino acid C-terminal segment of C/EBP (rC/EBP) that has the same binding characteristics as purified intact C/EBP [22, 28] . The in vitro synthesised C/EBP behaves identically to rC/EBP, in that both are able to bind to the E4-ATF (Fig. 3) and C/EBP binding sites with a Kj of approximately 2 nM as determined using the band-shift assay. We next used a series of mutant E4-ATF sites (Fig. 3) as competitors in band-shift assays to study the bases important for C/EBP binding. Mutation of nucleotides 5 (mut2) and 8 (mut4) abolish the ability of the site to compete for C/EBP binding and the inability of mutant 4 to do so indicates that C/EBP requires nucleotides beyond the ATF concensus for binding. This was further substantiated using methylation interference and copperphenanthroline footprinting on a 59 bp oligonucleotide encompassing the E4-ATF binding site. Methylation of two Gs within and one outside the ATF binding site interferes with C/EBP binding (Fig. 4) consistent with the results obtained with the mutant oligonucleotides. Copper-phenanthroline footprinting showed that a 16 bp sequence overlapping the ATF binding site is protected in both the upper and lower strand, although the 5' boundary in the upper strand was not very clear (Fig. 4) .
Finally we investigated whether C/EBP was able to bind the ATF site in vivo in transient transfection experiments. Using the expression vector pMSV-CEBP-wt we analysed the ability of C/EBP to stimulate transcription from a CAT-based reporter containing two E4-ATF binding sites in HeLa cells. Transcription was stimulated eight-fold (Fig. 5) , indicating that C/EBP was not only able to bind to the ATF site in vitro but also in vivo and that this binding mediates transcriptional activation. Two mutations of the E4-ATF site, mut4 and mut5, were also tested in the transient transfection experiments. Mut4, which failed to compete for C/EBP binding in the band-shift assay (Fig. 3 ) was unable to stimulate transcription (Fig. 5) , whereas mut5, which competed moderately well in vitro (Fig. 3) , was able to stimulate transcription about 5-fold (Fig. 5) . Thus it appears that C/EBP was able to interact specifically with ATF/CRE elements in intact cells. 
DISCUSSION
In the present study we have shown that the transcription factor C/EBP which is known to bind to the CCAAT and enhancer core elements was also able to bind to the ATF/CRE sites. One explanation for this may be the resemblance of the ATF/CRE binding sites to enhancer core sequences, such as that found in the SV40 enhancer [6] . The Gs at positions 2 and 5 in both binding sites are conserved ( by experiments in which mutations in this region disrupt C/EBP binding [7] . Interestingly, the somatostatin ATF site, which competes less well for CCAAT binding than the adenovirus sites, differs in this particular region by containing a C residue in position 7 instead of an A residue and we have shown that mutation of this C to an A allows competition of C/EBP binding at lower concentrations. Thus these observations support our suggestion that C/EBP binding to ATF/CRE sites may result from their homology to the enhancer core elements. The E4-ATF site we have used in our studies has been shown to bind not only the transcription factor ATF but also the factor E4F [29] . Although these proteins bind to the same site, they do so with different binding characteristics as two point mutants (pm2 and pm4) used by Rooney et al were able to distinguish between partially purified HeLa cell E4F (bound by pm2) and ATF (bound by pm4) binding [29] . On the basis of our results with the mutant sites 4 and 5 which correspond to pm4 and pm2, and comparison of the methylation interference pattern of the three proteins (Fig. 6) , we conclude that the sequence requirements for C/EBP resemble those of E4F more than ATF. They are not identical however, because C/EBP binding is competed by both the E3 and E4 ATF sites whereas E4F binding is not competed by the E3-ATF site [29] . Moreover, in contrast to both E4F and ATF, the binding of C/EBP is unaffected by methylation of G2, again indicating that it binds to ATF/CRE sites with different binding characteristics. When the C/EBP Gcontacts on the E4-ATF site are plotted on a DNA helix they are consistent with the idea that C/EBP 'wraps round' the helix [22, 30] .
Whilst this manuscript was in preparation Park et al. [31] showed that one of the CRE's (CRE1) present in the phosphoenolpyruvate carboxykinase promoter can bind C/EBP. These results agree with ours and their finding that CRE2 cannot bind C/EBP can be explained by the fact that the difference between CRE1 and CRE2 is at position 5 of the ATF consensus which we have shown to be important for C/EBP binding.
While it is clear that C/EBP is able to bind to a number of distinct sites it is also emerging that it may be only one member of a larger family of proteins [13, 14, 15] . Since their expression is regulated both in terms of tissue distribution and development [10, 15] , such degeneracy has the potential to generate complex regulatory mechanisms. It will therefore be important to establish whether C/EBP is able to recognise ATF/CRE elements in their natural environment. It is concievable that C/EBP may be able either to act as a transcriptional activator or to interfere with the activity of ATF/CREB if bound to ATF/CRE elements when a cell is in a particular stage of its development during which C/EBP is expressed. Preliminary results involving transient transfection have demonstrated the transcriptional activity of C/EBP (our results and [31] ) but they will have to be confirmed using natural promoters and endogenous C/EBP and ATF/CREB.
